Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
Article in Infectious Diseases and Therapy (July 2023)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
Article in Therapeutic Advances in Infectious Disease (January 2023)
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature
Article in Expert Review of Anti-infective Therapy (November 2022)